Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma (PEL-LL) in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.

Author Information (click to view)

Shin J, Lee JO, Choe JY, Bang SM, Lee JS,

Shin J, Lee JO, Choe JY, Bang SM, Lee JS, (click to view)

Shin J, Lee JO, Choe JY, Bang SM, Lee JS,


Cancer research and treatment : official journal of Korean Cancer Association 2016 6 10() doi 10.4143/crt.2016.076


Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma (NHL) arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea.

Submit a Comment

Your email address will not be published. Required fields are marked *

eleven + fifteen =